

**INVESTIGATION OF THE EFFECT OF STALANEV (STAVUDINE,
LAMIVUDINE AND NEVIRAPINE) TREATMENT ON SERUM
LACTATE LEVELS IN ADULTS ATTENDING BRIDH AND WIDH
OPPORTUNISTIC INFECTIONS CLINICS IN HARARE**

**A DISSERTATION SUBMITTED IN PARTIAL FULFILLMENT OF
THE REQUIREMENTS OF THE MASTERS DEGREE IN CLINICAL
BIOCHEMISTRY**

BY

GARIKAI MALUNGA

R962842L

DEPARTMENT OF CHEMICAL PATHOLOGY

UNIVERSITY OF ZIMBABWE

COLLEGE OF HEALTH SCIENCES

SEPTEMBER 2011

ABSTRACT

Background

Human Immunodeficiency Virus (HIV) and Acquired Immunodeficiency Syndrome (AIDS) have become a significant public health problem in Zimbabwe, threatening the socio-economic fibre of the country and placing a tremendous strain on the capacity of the health sector to respond to the needs of the population. Antiretroviral therapy (ART) has reduced morbidity and mortality due to HIV and AIDS. Although it has also improved the quality of life of people living with HIV and AIDS, concern has risen due to its association with challenges such as impaired glucose metabolism, insulin resistance, lactic acidosis, osteopenia and dyslipidemia. Although World Health Organization (WHO) has recommended phasing out stavudine in all ART regimens due to its association with mitochondrial toxicity thereby leading to lactic acidosis, Zimbabwe has continued to use it due to the limited resources available. This study assessed the development of hyperlactatemia in patients on antiretroviral therapy containing stavudine, lamivudine and nevirapine (STALANEV) attending Wilkins Infectious Diseases Hospital (WIDH) and Beatrice Road Infectious Diseases Hospital (BRIDH) OI clinics in Harare.

Study design and methods

One hundred and eighty (180) adults aged 20-60 years who were HIV infected and were about to be initiated on STALANEV at WIDH and BRIDH OI clinics were recruited into this prospective cohort study. All the participants were antiretroviral naïve before entering the study and were commenced on first line regimen of STALANEV and then

followed over a period of 4 months. The serum lactate levels of these participants were determined at enrolment (before commencing ART), after 2 months and 4 months on STALANEV treatment.

Results

Out of a total of 176 participants who completed the study, 95 (54.0%) developed hyperlactatemia over the 4-months follow-up period i.e. their serum lactate levels exceeded 2.5mmol/l. Eleven (6.8%) developed mild lactic acidosis i.e. their serum lactate levels exceeded 3.5mmol/l but were less than 4.0mmol/l. Serum lactate levels of 81 (46.0%) participants remained within the normal levels (0.5-2.5mmol/l) although there was an increase over the 4 months follow-up period. In all the participants, the mean difference between the serum lactate levels at baseline and 2 months after ART initiation was 20% whilst the one between 2 months and 4 months was 33%. A high increase of 59% was obtained between baseline serum lactate levels and the serum lactate levels after the 4 months follow-up period.

Conclusion

In this study population, STALANEV treatment led to an increase in serum lactate levels thereby, posing a danger for the development of lactic acidosis.

ACKNOWLEDGEMENTS

I would like to thank my dedicated supervisor Mr. T. Nyamayaro for the great help he gave me throughout this study. I am also grateful to the study participants, the City of Harare's City Health Department and my laboratory manager Mrs. Govere for their cooperation during this study. I would also like to thank the biostatistician Mr. W. Tinago for assisting with the statistical analysis of my data. Last but not least would like to thank my wife Nelliet for her emotional support.

TABLE OF CONTENTS

Abstract	ii
List of Tables.....	vii
List of Figures.....	viii
Abbreviations.....	ix
Chapter 1: Introduction and literature review.....	1
1.1 HIV infection.....	1
1.2 Structure of HIV and mechanism of infection.....	2
1.3 Antiretroviral therapy.....	4
1.4 Antiretroviral therapy in Zimbabwe.....	7
1.5 Complications of antiretroviral therapy.....	8
1.6 Hyperlactatemia and lactic acidosis during antiretroviral therapy	11
1.6.1 Physiology of lactate.....	11
1.6.2 Pathology of lactate.....	13
1.6.3 Lactic acidosis.....	14
1.6.4 Antiretroviral drugs and hyperlactatemia.....	16
1.7 Scope of the study.....	20

1.8	Aims of the study.....	20
1.9	Objectives of the study.....	21
	Chapter 2: Methodology and materials.....	22
2.1	Study design.....	22
2.2	Study population.....	23
2.3	Sample collection and analysis.....	25
2.4	Serum lactate determination.....	26
2.5	Principle of serum lactate determination.....	26
	Chapter 3: Results and statistical analysis.....	27
	Chapter 4: Discussion	38
	Recommendations.....	39
	Conclusion.....	40
	References.....	41

LIST OF TABLES

Table 1: Side effects of ARV drugs.....	9
Table 2: Baseline characteristics of the study participants.....	27
Table 3: Mean % change in serum lactate levels of participants over the 4 months period.....	32
Table 4: Serum lactate status of participants at the end of the 4 months period.....	34
Table 5: Categories and classification of serum lactate levels.....	35
Table 6: Univariate analysis of risk factors of hyperlactatemia.....	37

LIST OF FIGURES

Figure 1: Estimates of people living with HIV worldwide.....	1
Figure 2: Structure of HIV.....	3
Figure 3: The Cori cycle.....	12
Figure 4: Age of participants in the study.....	28
Figure 5: Age and sex of study participants.....	29
Figure 6: Baseline CD4 counts of the participants.....	30
Figure 7: Serum lactate levels of all study participants over the 4 months period....	31
Figure 8: Mean serum lactate profile of the participants over 4 months period.....	33
Figure 9: Serum lactate status of participants at the end of the 4 months period.....	36

ABBREVIATIONS

3TC	Lamivudine
ABC	Abacavir
ADP	Adenosine Diphosphate
AIDS	Acquired Immunodeficiency Syndrome
ANC	Antenatal Clinic
ARV	Antiretroviral
ATP	Adenosine Triphosphate
ATV	Atazanavir
AZT	Zidovudine
BRIDH	Beatrice Road Infectious Diseases Hospital
CD4	Clusters of Differentiation 4
d4T	Stavudine
ddl	Didanosine
DNA	Deoxyribonucleic acid
EFV	Efavirenz
FDA	Food and Drug Administration
FDC	Fixed Dose Combination
FI	Fusion Inhibitors
FTC	Emtracitabine
GI	Gastrointestine
HAART	Highly Active Antiretroviral Therapy
HIV	Human Immunodeficiency Virus
IDV	Indanavir

LDH	Lactate Dehydrogenase
LPV	 Lopinavir
NAD	Nicotinamide Adenine Dinucleotide
NADH	reduced Nicotinamide Adenine Dinucleotide
NNRTIs	Non Nucleotide Reverse Transcriptase Inhibitors
NRTIs	Nucleotide Reverse Transcriptase Inhibitors
NVP	Nevirapine
OIC	Opportunistic Infections Clinic
PIs	Protease Inhibitors
RNA	Ribonucleic Acid
RTV	Ritonavir
SQV	Saquinavir
STALANEV	Stavudine, Lamivudine and Nevirapine
TDF	Tenofovir
WHO	World Health Organization
WIDH	Wilkins Infectious Diseases Hospital